CRISPR Therapeutics AG [CRSP] stock prices are up 0.44% to $56.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The CRSP shares have gain 3.60% over the last week, with a monthly amount glided 10.65%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on September 18, 2025, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $70. Previously, Evercore ISI upgraded its rating to Outperform on February 14, 2025, and elevated its price target to $99. On February 12, 2025, upgrade upgraded it’s rating to Hold but maintained its price target of $35 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $65 on February 03, 2025. Needham reiterated its recommendation of a Buy and reduced its price target to $84 on August 06, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on August 02, 2024, and assigned it a price target of $90.
The stock price of CRISPR Therapeutics AG [CRSP] has been fluctuating between $30.04 and $78.48 over the past year. Currently, Wall Street analysts expect the stock to reach $66.33 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $56.71 at the most recent close of the market. An investor can expect a potential return of 16.96% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
The CRISPR Therapeutics AG [NASDAQ:CRSP] reported sales of 38.34M for trailing twelve months, representing a surge of 47.67%. Gross Profit Margin for this corporation currently stands at -2.17% with Operating Profit Margin at -12.21%, Pretax Profit Margin comes in at -12.42%, and Net Profit Margin reading is -12.52%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.25 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 55.67 points at the first support level, and at 54.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 57.29, and for the 2nd resistance point, it is at 57.86.
Ratios To Look Out For
It’s worth pointing out that CRISPR Therapeutics AG [NASDAQ:CRSP]’s Current Ratio is 16.22. On the other hand, the Quick Ratio is 16.22, and the Cash Ratio is 1.89. Considering the valuation of this stock, the price to sales ratio is 140.96, the price to book ratio is 2.78.
Transactions by insiders
Recent insider trading involved Prasad Raju, Chief Financial Officer, that happened on Dec 22 ’25 when 10000.0 shares were sold. Officer, RAJU PRASAD completed a deal on Dec 22 ’25 to buy 10000.0 shares. Meanwhile, Chief Executive Officer Kulkarni Samarth sold 50895.0 shares on Oct 17 ’25.
